News

P1vital announces the official launch of the Reward Task Optimisation Consortium – RTOC

Wallingford, UK, July 22, 2019 Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium (RTOC). Emerging from the ECNP Experimental Medicine Network and formally launched in April 2019, RTOC is a pre-competitive initiative which aims to advance the development of clinical tools to measure impaired motivation in… Read more »

First walk in clinic using i-spero® opened in Faversham on 4 July 2019!

i-spero® is being used as a part of Low mood, depression and anxiety walk in clinic in Faversham starting on Saturday 6 July. Click here to read more. Read more about i-spero®

Funding awarded to P1vital Products will help transform treatment of depression using digital technology.

(8 May 2019) P1vital Products (PPL) has, in partnership with Canterbury and Coastal CCG, University of Kent, and the mental health charity MIND, been awarded £815,506 by the UK’s innovation agency, Innovate UK, to advance research to improve the treatment of depression. The funding will enable a real-world evaluation of novel digital technology developed by… Read more »

European Neuropsychopharmacology article talks about predicting treatment response

New article on predicting antidepressant treatment response was published in November issue of European Neuropsychopharmacology which discusses the results of our Proof of Concept study conducted in the UK. To read full article, click here.

The Pharmaceutical Journal speaks about P1vital® PReDicT Test

The Pharmaceutical Journal examines personalised treatment to depression including P1vital® PReDicT Test which is being used in PReDicT clinical study across 5 European countries.   To read the full article, click here.

Clinical Psychiatry News discusses PReDicT study

Following ECNP Congress where Catherine J. Harmer, DPhil talked about early change in emotional processing predicting antidepressant response, Clinical Psychiatry News discusses PReDicT study and the P1vital® PReDicT Test which is being used in clinical study across 5 European countries: France, Germany, Spain, The Netherlands and the UK. To read the full article, click here.

MindTech talks about PReDicT study

University of Nottingham, MindTech article talks about PReDicT study and the P1vital® PReDicT Test which is being used in clinical study across 5 European countries: France, Germany, Spain, The Netherlands and the UK. To read the full article, please the below link. https://www.mindtech.org.uk/research/research-themes/objective-assessment-and-monitoring/predict

P1vital Products Awarded one of the SME stands at BIO 2017

We are very excited to announce we have won a trade show stand at 2017 BIO International Convention. 2017 BIO is the largest, most influential biotech Convention in the world is coming to San Diego, June 19-22, 2017. Experience powerful business partnering, benefit from invaluable education sessions and network with 16,000+ of biotech’s best and… Read more »

P1vital Secures HORIZON 2020 SME Instrument Funding Award

€4m Funding from EU Commission for New Healthcare Innovation to improve the Treatment of Depression Innovative Oxfordshire based healthcare company P1vital Ltd announces that it has been awarded €4 Million from the EU Commission for further clinical research across Europe of a novel medical device to improve the treatment of depression. The PReDicT (Predicting Response… Read more »

NHS Foundation Trust discusses PReDicT Project

Oxford Health NHS Foundation Trust about PReDicT Project discusses P1vital Products Limited and the P1vital® PReDicT Test which is being used in clinical study across 5 European countries. To read the full article, click here.

Next Page »